肌无力重症治疗市场

Report Highlights

The scope of this report covers the different types of Myasthenia Gravis Treatment along with emerging product launches for the treatment of Myasthenia Gravis Treatment. The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each treatment, medication, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional Myasthenia Gravis Treatment markets; it explains the major market drivers of the Global Myasthenia Gravis Treatment industry, current trends within the industry, major applications, and the regional dynamics of the Global Myasthenia Gravis Treatment Market.

该报告以特别关注供应商景观的特殊重点结束，其中包括全球肌无力疗程的主要供应商的详细概况。最近的合并和收购，本报告还可以满足新产品开发。

Report Includes

• 40 tables and 48 figures
• 对全球肌无力的重力治疗市场的最新分析。
• Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
• 估计全球肌无力治疗市场的市场规模和收入预测，以及通过治疗，药物，最终用户和地区进行相应的市场份额分析。
• 新兴技术趋势，差距和机遇的亮点估计了对肌无力治疗的当前和未来需求，确定最适合这种需求的公司。
• In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
• Identification of promising new drugs, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
• 与整体全球经济相比，COVID-19对肌无力的Gravis治疗市场的影响。
• 深入了解主要肌无力的重力治疗制造商及其主要竞争格局的增长发展策略
• 领先市场参与者的描述性公司资料，Alexion Pharmaceuticals Inc.，Argenx SE，Astellas Pharma Inc.，Curavac，Inc。，Grifols SA，UCB Pharma S.A.，Immunovant Inc.，Mitsubishi Tanabe Tanabe Pharma Corporation等。

概括

肌无力重症，一种罕见的神经肌肉自身免疫性疾病会导致骨骼肌无力。大部分受影响的身体部位是眼睛，脸部和喉咙肌肉。当肌肉与神经细胞之间的通信中断时，通常会发生这种情况。在肌无力中，抗体与负责阻断传播的神经信号传递的蛋白质结合。在某些情况下，抗体与乙酰胆碱受体结合，而在其他情况下，抗体攻击另一种称为肌肉特异性激酶的蛋白质。该疾病没有永久治愈方法，但是进行了药物和手术以减少疾病的症状数量。在此过程中使用的一些常见药物是胆碱酯酶抑制剂，皮质类固醇，免疫抑制剂，血浆置换，静脉免疫球蛋白和单克隆抗体。